Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubular network agent and is one of the most active agents in the treatment of metastatic castrate resistant prostate cancer (CRPC) and other variety of cancers. Taxotere has poor solubility and is designed to be administered with Tween 80 in ethanol. This vehicle causes acute hypersensitivity reaction. By removing toxic detergent used in Taxotere, the form of LE-DT, shows reduced toxicity and comparable therapeutic efficacy in pre-clinical study. The clinical evidence obtained from the NeoPharm Phase I study shows fewer side effects and possibly administered at higher dose to induce greater effectiveness of LE-DT. The current Phase II study is designed to accomplish the following objectives:
- Assess the antitumor effect indicator serum prostate specific antigen (PSA) following the intravenous (IV) administration of 110 mg/m2 LE-DT every three weeks in patients with metastatic castrate resistant prostate cancer
- To evaluate the measurable soft tissue disease response using the response evaluation criteria in solid tumor (RECIST) methodology
- To evaluate the progression-free survival (PFS) and overall survival (OS)
- To correlate PSA expression with tumor response
- To evaluate the safety of LE-DT at 110 mg/m2 level, in particular peripheral neuropathy, water retention as well as myelotoxicity
- To evaluate the quality of life (QOL)
研究概览
研究类型
阶段
- 阶段2
联系人和位置
学习地点
-
-
District of Columbia
-
Washington、District of Columbia、美国、20007
- Georgetown University Medical Center
-
-
Oregon
-
Portland、Oregon、美国、97213-2933
- Providence Portland Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Be 18 years or older and male.
- Have histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate.
- Patients without evidence of PSA progression must have clinical or radiographic evidence of metastatic disease.
- Must have castrate levels of testosterone (serum testosterone less than 50ng/dl) by either being on androgen ablation therapy with a luteinizing hormone-releasing hormone (LHRH) agonist or have had a prior bilateral orchiectomy.
- Patients must have documented evidence of disease progression: progressive disease is defined as a minimum of three consecutive elevations in PSA each obtained a minimum of one week apart with the last value being greater than 2 ng/mL and/or new metastatic lesions on bone scan (minimum of 2) and/or new or progressive disease on CT or MRI scan.
For patients on an antiandrogen (flutamide, nilutamide, bicalutamide)
- If given as part of first line therapy or for patients who did respond to antiandrogen second line therapy, the patient must demonstrate progression of disease at least 4 weeks beyond discontinuation of such agents to rule out an antiandrogen withdrawal response.
- If given as a second line therapy and the patient did not respond or had a decline in PSA for less than 3 months, it is not required to observe for a withdrawal response.
- Chemotherapy-naïve patients (unlimited prior regimens of hormonal therapy are acceptable).
- Have no other malignancy within the past five years, except non-melanoma, skin cancer.
Have recovered from acute toxicities of prior treatment:
- Greater than or equal to 4 weeks must have elapsed since receiving hormonal therapy (except for chronic non-investigational gonadotropin releasing hormone analogs or other primary androgen suppressive therapy which are required), biologic agents or any investigational agent (palliative bisphosphonate therapy for bone pain can be administered as clinically indicated).
- Greater than or equal to 4 weeks must have elapsed since receiving any radiotherapy
- Greater than or equal to 2 weeks must have elapsed since any prior surgery or granulocyte-stimulating growth factor therapy.
Have the following hematology levels at Baseline:
- Absolute Neutrophil Count (ANC) greater than or equal to1,500 x 106 cells/L
- Platelets greater than or equal to 100 x 109 cells/L
- Hemoglobin greater than or equal to 9 g/L.
Have the following chemistry levels at Baseline:
- AST (SGOT), ALT (SGPT) less than or equal to 1.5 x ULN
- Total bilirubin less than or equal to 1.5 ULN
- Creatinine less than or equal to 1.5 ULN; or 24-hour creatinine clearance greater than 60 mL/min
- Normal serum electrolytes and magnesium levels
- Have a life expectancy of greater than or equal to 12 weeks.
- Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.
- Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee (EC)/Institutional Review Board (IRB)-approved written informed consent form (ICF) prior to receiving any study related procedure.
Exclusion Criteria:
- Patient has radiographic evidence of active (symptomatic, untreated) intraparenchymal brain metastases; any meningeal metastases; or asymptomatic untreated intraparenchymal brain metastases requiring treatment.
- Patient has received prior chemotherapy for metastatic prostate cancer.
- Patient has a known infection with human immunodeficiency virus or active viral hepatitis.
- Patient has active heart disease including myocardial infarction or congestive heart failure within the previous 6 months, symptomatic coronary artery disease, or uncontrolled arrhythmias.
- Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug (e.g., uncontrolled bleeding or bleeding diathesis).
- Any active infection requiring parenteral or oral antibiotics.
Patient treated with any of the following:
- Taxol, Taxotere or Abraxane for prostate cancer or any prior malignancy
- Concurrent radiation therapy (except for palliative radiotherapy for symptomatic bone metastasis which can be administered as clinically indicated)
- Patient has pre-existing peripheral neuropathy of Grade greater than 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Liposome Entrapped Docetaxel (LE-DT)
Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
|
110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Assessment of serum PSA
大体时间:1 year
|
Measure serum PSA after 2, 4 and 6 cycles of treatment
|
1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
RECIST method assessment
大体时间:1 year
|
Measurable soft tissue disease response based on the RECIST method, PFS, and OS will also be assessed after 2, 4 and 6 cycle to determine the treatment effectiveness with LE-DT after treatment
|
1 year
|
合作者和调查者
调查人员
- 首席研究员:Nancy A Dawson, M.D.、Georgetown University
- 首席研究员:Brendan D Curti, M.D.、Providence Health & Services
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.